SemBioSys cuts jobs, plans company sale or shutdown

Canadian biotech company SemBioSys Genetics is exploring its strategic alternatives, including a corporate sale or merger, a strategic transaction for either insulin or Apo, an asset sale, a significant restructuring and recapitalization or a wind down of the company's operations. According to a release, the company has already laid off an unspecified number of employees. SemBioSys has been using patented plant seed, oil body and expression technology platforms to develop biosimilar drug candidates and proteins. SemBioSys release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.